Doctor D's Resume
Paolo B. DePetrillo, M.D.
SNBL Clinical Pharmacology Center, Inc.
Baltimore, MD 21201
- Works closely with the President to develop and implement policies and procedures that ensure high quality service.
- Oversees SNBL-CPC Research Physicians.
- Functions as the Principal Investigator and Sub-Investigator for Clinical Research Studies, ensuring that all protocol guidelines are met.
- Adherence to Good Clinical Practices (GCP), and SNBL-CPC’s Standard Operating Procedures (SOPs).
- Maintains external relationships with physicians, hospitals and community health centers to assist with study needs and participant recruitment.
- Performs physical exams on study participants.
- Evaluates clinical laboratory and study examinations.
- Monitors and documents all participant’s adverse events, medical condition and response to study medications and treatments.
- Ensures that all protocol guidelines are met.
- Pursues clients and responds to client requests.
- Attends industry events to ensure optimum exposure of SNBL CPC.
Applied Pharmacogenomics, LLC, Bethesda, MD, USA
Internal Medicine and Clinical Pharmacology MDLive
ACTIVE MEDICAL LICENSES
Rhode Island, Massachusetts, and Maryland
Brown University Providence, RI, USA: Sc.B., Biology, MD
Clinical Pharmacology Fellowship
(Paul Calabresi, MD & Darrell R. Abernethy, MD, PhD)
Brown University/Roger Williams Hospital
Internal Medicine Residency
Brown University/Roger Williams Hospital
POST-GRADUATE HONORS AND AWARDS
Association Foundation Faculty
Public Health Service Achievement Award
Public Health Service Hazardous Duty Award
Pfizer Clinical Pharmacology
United States Public Health Service Commander (O-5) Active Reserve
United States Public Health Service Commander (O-5)
American Board of Clinical Pharmacology
Certificate Number 93144
American Board of Internal Medicine
Certificate Number 100003
PAST ACADEMIC APPOINTMENTS
Adjunct Associate Professor
Wake Forest University Health Sciences
Dept of Physiology & Pharmacology
Medical Center Boulevard
Winston-Salem, NC 27157-1083 USA
Senior Research Investigator
Section on Clinical and Biochemical Pharmacology
Laboratory of Clinical Studies
National Institute on Alcohol Abuse and Alcoholism
National Institutes of Health
Bethesda, MD, USA
Assistant Professor of Medicine
Chief Medical Resident
Providence, RI, USA
PAST HOSPITAL APPOINTMENTS
Warren Grant Magnuson Clinical Center
National Institutes of Health
Substance Abuse Treatment Center
Roger Williams Medical Center
Providence, RI, US
Active Medical Staff
Roger Williams Hospital
Associate Active Medical Staff
Roger Williams Hospital
Senior Assistant Surgeon
Lewisburg Penitentiary Hospital
United States Public Health Service
Lewisburg, PA, US
PAST CLINICAL APPOINTMENTS
New Bedford Area Center for Human Services
Drug Treatment Program
New Bedford, MA,USA
Data Monitoring Board for Cooperative Study 1008, “A Multicenter Efficacy/Safety Trial of Buprenorphine for Treatment of Opiate Dependence
Ad Hoc Committee for the NIDA/VA Substance Abuse Medication Development Research Units Substance Abuse Committee
American Society for Clinical Pharmacology and Therapeutics
Human Subjects Institutional Review Board (National Institutes of Health, NINDS)
Human Subjects Institutional Review Board (National Institutes of Health, NIAAA)
Human Subjects Institutional Review Board, Clinical Affairs Committee, and Clinical Competency Committee (Roger Williams Hospital, Brown Univ)
- Swift RM, Dudley M, DePetrillo PB, Camara P, Griffiths W. Altered methadone pharmacokinetics in pregnancy: Implications for dosing. J Subst Abuse 1:453-460, l989.
- DePetrillo PB, Swift RM, Ambroise C, Abernethy DR. High- performance liquid chromatographic determination of 3':5'cyclic adenosine monophosphate in human platelets. J Chromatogr 527(2):421-427, l990.
- Swift RM, DePetrillo PB. Human leukocyte beta-adrenergic stimulated cyclic AMP in ethanol intoxication and withdrawal. Alcohol Clin Exp Res 14(1):58-62, l990.
- Swift RM, DePetrillo PB. Cocaine abuse and dependence. RI Med J 73(6):265-70, 1990.
- DePetrillo PB, Swift RM. Ethanol exposure results in a transient decrease in cAMP in human platelet cAMP levels: Evidence for a protein kinase C mediated process. Alcohol Clin Exp Res 16(2):290-294, l992.
- DePetrillo PB, Kurl RN. Stimulation of protein kinase C by 2, 3, 7, 8- tetrachlorodibenzo-p-dioxin (TCDD) in rat thymocytes. Toxicol Lett 69(1):31-36, 1993.
- DePetrillo PB, Liou CS: Ethanol exposure increases total PKC activity in human lymphocytes.
- Kurl RN, DePetrillo PB, Olnes MJ: Inhibition of Ah (dioxin) receptor transformation by 9-hydroxy ellipticine: role of protein kinase C. Biochem Pharmacol 46(8):1425-1433, 1993.
- DePetrillo PB, Butte AJ. Derivation of a scale-independent parameter which characterizes genetic sequence comparisons. Comput Biomed Res 26:517-540, 1993.
- DePetrillo PB, Abernethy DR, Wainer IW, Andrawis NS. Verapamil decreases lymphocyte protein kinase C activity in humans. Clinical Pharmacol Ther 55(1):44-48, 1994.
- DePetrillo PB. Effects of chronic alcohol use and age on human lymphocyte protein kinase C activity. Pharmacol Biochem Behav 48(4):999-1004, 1994.
- DePetrillo PB, Rice, JM. Methadone dosing and pregnancy: Impact on program compliance. Int J Addict 30(2) 207-217, 1995.
- DePetrillo PB: Calcium-activated neutral protease activity is decreased in PC12 cells after ethanol exposure. J Neurochem 68:1863-1869. 1997.
- DePetrillo PB, White KV, Liu M, Hommer D, Goldman D. Effects of alcohol use and gender on the dynamics of EKG time-series data. Alcohol Clin Exp Res 23: (4) 745-750, 1999.
- DePetrillo PB, Speers D’A, Ruttiman UE. Determining the Hurst exponent of fractal time series and its application to EKG analysis. Comput Biol Med 29:6, 393-406, 1999.
- DePetrillo PB, Bennett AJ, Speers d’A, Suomi SJ, Shoaf SE, Karimullah K, Higley JD. Ondansetron blockade of ketamine-induced effects on electrocardiographic signal dynamics in rhesus monkeys. Eur J Pharmacol 391:(1-2), 113-119, 2000.
- DePetrillo PB, Yang Q, Rackoff J, SanMiguel A, Karimullah K. Surface fractal computation and its application to immunofluorescent histochemical studies of calpain and calpastatin in PC12 cells. J Neurosci Meth 103(2):191-197, 2000.
- Karimullah K, George DT, DePetrillo PB. The time-course of electrocardiographic interbeat interval dynamics in alcoholic subjects after short-term abstinence. Eur J Pharmacol 427(3): 229-235, 2001.
- Rackoff J, Yang QF, DePetrillo PB. Inhibition of rat PC12 cell calpain activity by glutathione, oxidized glutathione and nitric oxide. Neurosci Lett 311(2): 129-132, 2001.
- Bennett AJ, Sponberg AC, Graham T, Suomi SJ, Higley JD, DePetrillo PB. Initial alcohol exposure results in decreased heart rate variability in alcohol-naĢve rhesus monkeys. Eur J Pharmacol 433:169-172, 2001.
- Wan W, DePetrillo PB. Ritonavir inhibition of calcium-activated neutral proteases. Biochem Pharmacol 63(8):1481-1484, 2002.
- Wan W, DePetrillo PB. Ritonavir protects hippocampal neurons against oxidative stress-induced apoptosis. Neurotoxicology. 23(3):301-306, 2002.
- DePetrillo PB. Calpains - A review of the recent patent literature. IDrugs. 5:568-576, 2002.
- Li XW, DePetrillo PB. Corticosterone increases 5-HT3 receptor mRNA in PC12 cells. Neurosci Lett 331(2):143-145, 2002.
- Herman AI, Philbeck JW, Vasilopoulos NL, DePetrillo PB. The serotonin transporter promoter polymorphism and differences in alcohol consumption behaviour in a college student population. Alcohol Alcohol 38(5):446-449, 2003.
- Bennett AJ, DePetrillo PB. Sex differences in total body water in rhesus macaques estimated by ethanol dilution. J Med Primatol 33(3):163-166, 2004.
- Herman AI, Kaiss KM, Ma R, Philbeck JW, Hasan A, Dasti H, DePetrillo PB. Serotonin transporter promoter polymorphism and monoamine oxidase type A VNTR allelic variants together influence alcohol binge drinking risk in young women. Am J Med Genet B Neuropsychiatr Genet. 2005 Feb 5;133(1):74-8.
- Fontenot MB, Padgett EE 3rd, Dupuy AM, Lynch CR, De Petrillo PB, Higley JD. The effects of fluoxetine and buspirone on self-injurious and stereotypic behavior in adult male rhesus macaques. Comp Med. 2005 Feb;55(1):67-74.
- Bennett AJ, DePetrillo PB. Differential effects of MK801 and lorazepam on heart rate variability in adolescent rhesus monkeys (macaca mulatta). J Cardiovasc Pharmacol. 2005 May;45(5):383-8.
- Sabetta JR, DePetrillo P, Cipriani RJ, Smardin J, Burns LA, et al. (2010) Serum 25-Hydroxyvitamin D and the Incidence of Acute Viral Respiratory Tract Infections in Healthy Adults. PLoS ONE 5(6): e11088. doi:10.1371/journal.pone.0011088
- Swift RM, DePetrillo PB, Brown WA, Liepman M, Nirenberg TD. Human lymphocyte beta-adrenergic activity in ethanol withdrawal. Presented at Am. College Neuropsychopharmacology Meeting, l986.
- Swift RM, DePetrillo PB. Effect of ethanol on human mononuclear cell cyclic AMP formation. Clin Research 34(2):407A, l986.
- Swift RM, DePetrillo PB, Dudley M, Griffiths W, Dextraze P. Altered methadone pharmacokinetics in pregnancy with twins. Clin Pharmacol Ther 41(2):231, l987.
- Swift RM, Sullivan JT, DePetrillo PB. An open study of clonidine detoxification in the general hospital. Clin Pharmacol Ther 43(2):l86, l988.
- DePetrillo PB. Dynamics of plasma adenosine during ethanol withdrawal. Clin Research 40:410A, l992.
- DePetrillo PB, Peterson D. Effect of magnesium sulfate on alcohol withdrawal symptomatology. CLIN PHARMACOL THER 51: (2) 169-169 FEB 1992
- DePetrillo PB, Kurl RN. 1,2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) stimulates protein kinase C (PKC) activity in immature thymocytes. FASEB J 6: (5) A1885-A1885 Part 2 FEB 28 1992
- DePetrillo PB, Andrawis NS, Abernethy DR. Verapamil (VER) decreases lymphocyte protein kinase C (PKC) activity in humans. The Pharmacologist. 34(3):91, l992.
- DePetrillo PB. Alterations in circulating lymphocyte protein kinase C (PKC) activity associated with chronic alcohol exposure. Clin Pharmacol Ther. 53(2):176, 1993.
- Kurl RN, DePetrillo PB, Olnes M. Role of phosphorylation in transformation of the Ah receptor-effect of 9-hydroxy ellipticine an inhibitor of protein kinase C (PKC). Proceedings of the American Association for Cancer Research. 34:176, 1993.
- DePetrillo PB. Ethanol inhibits calcium-stimulated protease activity. Clin Pharm Ther. 61(2):190, 1997.
- DePetrillo PB. Calcium-channel blockers prevent ethanol-induced decreases in calpain activity in PC12 cells. CLIN PHARMACOL THER 63: (2) 204-204 FEB 1998
- DePetrillo PB, Ruttimann U. Method for determining the Hurst exponent of a fractal time series and its applications to EKG signal analysis. Clin Pharm Ther. 65(2):158, 1999.
- DePetrillo PB, White KV, Liu M, Hommer D, Goldman D. Alcohol consumption is associated with decreased cardiac signal complexity. Clin Pharm Ther. 65(2):158, 1999.
- Graham S, Umhau J, DePetrillo PB. Hurst and RSA measures in healthy controls, alcoholics, and perpetrators of domestic violence. RSA 1999.
- Bennett AJ, DePetrillo PB, Shoaf SE, Lindell S, Shannon CS, Suomi SJ, Higley JD. Interindividual differences in CSF 5HIAA concentrations alter rhesus monkeys' cardiac signal complexity in response to serotonergic agents. American College of Neuropsychopharmacology, Acapulco, Mexico. 1999.
- Krupnick S, Peterson DJ, McDonough MK, DePetrillo PB:. The typology of alcohol withdrawal syndrome (AWS): implications for diagnosis and treatment. 6th Annual NPNR Conference. 19:2000.
- Bennett AJ, Sponberg AC, Graham T, Lindell S, Suomi SJ, Higley JD, DePetrillo PB. Initial alcohol exposure results in stress-dependent acute increases and subsequent decreases in CSF 5-HIAA concentrations and cardiac signal complexity in alcohol-naĢve rhesus monkeys. Presented at the annual Experimental Biology meeting, Orlando, FL. 2001.
- Hibbeln JR, DePetrillo PB, Champoux M, Higley JD, Lindell S, Shannon C, Suomi SG, Salem N. Improvements in heart rate variability among adolescent rhesus monkeys fed formula supplemented with DHA and AA as infants: Neuropsychiatric implications. Inform 11(5), 2000.
- Yang QF, DePetrillo PB. Calpain inhibitor and ritonavir block glutamate cytotoxicity in PC12 cells. MOL BIOL CELL 11: 411A-412A Suppl. S DEC 2000
- Graham TA, Bennett AJ, Lindell SG, DePetrillo PB, Higley JD. A single alcohol exposure changes heart rate variability in rhesus monkeys. ASP 2000.
- Graham T, Bennett AJ, Lindell S, Sponberg AC, DePetrillo PB. Change in cardiac signal dynamics associated with MK-801 and lorazepam in rhesus monkeys. 24th Meeting of the American Society of Primatologists, Abstract number 59, 2001.
- Depetrillo PB, Wan W. Ritonavir Is A Competitive Inhibitor Of Calcium-activated Protease (Calpain) Activity In PC12 Cells. CLIN PHARMACOL THER 69: (2) P36-P36 Suppl. S FEB 2001
- Bennett AJ, Sponberg AC, Graham T, Lindell S, Suomi SG, Higley JD, DePetrillo PB. Initial alcohol exposure results in stress-dependent acute increases in CSF 5-HIAA concentrations and cardiac signal complexity in alcohol-naive rhesus monkeys. FASEB J 15: (5) A911-A911 Part 2 MAR 8 2001
- DeVinney BJ, DePetrillo PB, Yang JJ, Morin LC, Suomi SJ. CSF 5-HIAA and HVA associated with weaning aggression among rhesus monkey mothers at the N. I. H field station. ASP 2002.
- Bennett AJ, Garrett-Goodyear CH, Higley JD, DePetrillo PB. Cardiac reactivity as a predictor for response to alcohol in rhesus monkeys. Alcohol Clin Exp Res. 2002 26(5):180A (1049).
- Abernethy DR, DePetrillo PB: Withdrawal from non-abused drugs. In Encyclopedia of Drugs and Alcohol, New York, Macmillan, Inc. 1993.
- Olnes MJ, DePetrillo PB, Kurl RN: Mechanism of 9-hydroxy ellipticine induced inhibition of hepatic aryl hydrocarbon hydroxylase. In Cytochrome P450. 8th International Conference, Paris, John Libbey Eurotext, 1994:729-732.
- DePetrillo PB, McDonough MK. Alcohol Withdrawal Treatment Manual. FTS. Glen Echo, MD, USA 1999.
SELECTED MANUSCRIPTS IN REVIEW
- DePetrillo PB. Relationship of solar cycles to influenza A epidemics from 1734 to present.
SELECTED MANUSCRIPTS IN PREPARATION
- DePetrillo PB. Bootstrap resampling routines for determining the power of genetic association studies.
- DePetrillo PB. Underestimates of the magnitude of the Type I error in allelic frequency-based analyses of case-control data in genetic association studies demonstrated by bootstrap resampling.
Alcohol and Alcoholism; Alcoholism Clinical and Experimental Research; American Journal of Cardiology; American Journal of Medical Genetics; Archives of General Psychiatry; Clinical Pharmacology and Therapeutics; European Journal of Clinical Pharmacology; Journal of Pharmacology and Experimental Therapeutics; Life Sciences; Neuroscience Letters; Pharmacological Reviews; iDrugs
Determining the Hurst exponent of time series data
U.S Patent No. 6,144,877 (2000)
Methods of and compounds for inhibiting calpains
U.S Patent No. 6,448,245 (2002)
- A Randomized, Double-Blind (Sponsor-Open), Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Non-Japanese and Japanese Subjects
- An Ascending, Single Oral Dose, Double-Blind, Randomized, Placebo-Controlled Study Assessing the Safety, Tolerability, and Pharmacokinetics of DSP-1200 in Fasted Healthy Adult Male Subjects
- A Phase 1 Single Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of XXXXX Fixed-Dose Combination (FDC) tablets in Healthy Japanese and Caucasian Subjects
- A Phase 1, Open-Label Study To Assess The Safety And Pharmacokinetics Of A Single Dose of XXXX In Subjects With Edematous Fibrosclerotic Panniculopathy
- A Phase 1, Open-label Study in Healthy Adult Subjects to Evaluate the Effect of Single and Multiple Oral Doses of XXXX when Coadministered with Single Oral Doses of Midazolam and to Evaluate the Pharmacokinetics of a Single Oral Dose of An Alternate Tablet Strength of XXXX Alone
- A Randomized, Double-blind, Positive and Placebo-controlled, Three-arm Parallel Group Study of the Effects of XXXX at Therapeutic and Supra-Therapeutic Doses, on the QTc and other Electrocardiogram (ECG) Parameters in Healthy Subjects
- Single-Dose, Randomized, Crossover Study to Compare the Relative Oral Bioavailability of XXXX (Reference) and Suspension B (Test) in Healthy Young Adult Subjects
- A Phase I, Dose-Escalation Study to Determine the Safety, Tolerability and Maximum Tolerated Dose XXXX in Normal Healthy Volunteers
- A Randomized, Double-Blind, Parallel-Group Safety and Pharmacokinetic Similarity Study of XXXX and XXXX Following a Single Subcutaneous Injection in Healthy Subjects
- A Single- and Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Intravenous Doses of XXXX in
- Patients with Mild Cognitive Impairment due to Alzheimer’s Disease or Mild to Moderate Alzheimer’s Disease
- Phase II, Randomized, Placebo-controlled, Double-blind, Safety and Immunogenicity Trial of XXXX Vaccine in Healthy Adults.
- A Phase II, Randomized, Comparative, Observer-Blind, Multi-Center Study Evaluating the Safety and Immunogenicity of the Liquid Formulation of Group B XXXX Vaccine and of the Lyophilized Formulation of Group B XXXX Vaccine in Healthy Non-Pregnant Women aged 18 to 40 Years.
- A Phase I Study to Evaluate the Safety and Pharmacokinetics of XXXX in Healthy Volunteers.
- A Phase 1 single-center (U.S.), open label, dose escalation study of the safety and pharmacokinetics of single doses of intravenous XXXX in healthy adult subjects.
- A Randomized, Repeat-Dose, Crossover Study to Characterize COX-1and COX-2 Inhibition in Healthy Subjects Administered XXXX 5mg and 10 mg and XXXX 15 mg Tablets.
- Multi-Center, Open-label, Single-Arm Study to Assess the Safety and Contraceptive Efficacy of a Levonorgestrel-containing Intravaginal Ring during a Treatment Period of one year in healthy women 18 to 35 years of age.
- A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-Controlled, Single Ascending Dose Study To Investigate the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of XXXX In Subjects With Idiopathic Parkinson’s Disease.
- A Phase III, Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Immunogenicity of Three Consistency Lots and a High Dose Lot of XXXX in Healthy Adults.
- A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of intravenously Administered XXXX in Patients with Progressive Supranuclear Palsy.
- A Phase 1 Multiple Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of XXXX in Healthy Japanese and Caucasian Volunteers.
- Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of XXX.
- A Phase 1b, 2-period, Open label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XXXX in subjects with Parkinson's Disease and Motor Fluctuations.
- A Phase I, Randomized, Double-Blind, Single-Dose, Four-Period, Full Cross-Over Study Evaluating the Safety and Pharmacokinetics of Two Doses of XXX Inhalation Aerosol and Two Doses of XXX Inhalation Aerosol in Japanese Healthy Volunteers
- A Phase I, Randomized, Double-Blind, Single-Dose, Three-Period, Three-Treatment, Cross-Over Study Evaluating the Pharmacokinetics and Safety of a Single Dose of XXX Inhalation Aerosol, a Single Dose of XXX, and a Single Dose of Open-label XXX in Healthy Volunteers
- Phase II, Randomized, Placebo-controlled, Double-blind, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in Healthy Adults
- A Randomized, Placebo-controlled, Double-blind Dose-escalation and Food Effect Study of the Safety, Tolerability, and Pharmacokinetics (PK) of Single Doses of XXX Administered to Healthy Subjects
- A Pilot Bioavailability (BA) Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of XXX Tablet Formulations
- A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of the Human Cytomegalovirus Vaccine in Healthy Adults.
- A Study to Assess Persistence of the Immune Response after Vaccination with a staphylococcus aureus 4-antigen (sa4ag) vaccine.
- A Single Center, Single dose, Double-blind, Two-way Crossover, Placebo-controlled, Randomized NeuroCart Validation Study based on an Evaluation of the effects of Lorazepam 2 mg on Sedation, Cognition and Electroencephalography (EEG) in Healthy Male Volunteers
- A Phase I, Randomized, Double-Blind, Placebo-Controlled, Two‑Period, Ascending Dose, Incomplete Block, Crossover Study to Assess the Safety and Pharmacokinetics of Two Doses of XXX in Japanese Healthy Subjects Following a Single Dose and After Chronic Dosing for 7 Days
- A Phase I, Single Dose, Randomized, Crossover Relative Bioavailability Study to Compare oral XXX Capsules and Suspension in Healthy Adult Subjects.
- A Study of the Safety, Tolerability and Pharmacokinetics of XXX Administered Once in Healthy Volunteers
- A Multi-Center Evaluation of BD Vacutainer® Plasma Cyclops Blood Collection Tube for Selected Infectious Disease Analytes
- A Phase I, Randomized, Double-Blind Within Device, Single-Dose, Four-Period, Six-Treatment, Cross-Over Study Evaluating the Safety and Pharmacokinetics of Three Doses of XXX Inhalation Aerosol, One Dose of XXX Inhalation Aerosol, and Two Doses of XXX Aerosol in Healthy Volunteers
- A Randomized, Two-Period Crossover Study to Determine the Comparative Bioavailability of Testosterone Absorption After Administration of Testosterone Gel (T-Gel 1.5% or T-Gel 3.0%) to the Anterior/Lateral Thigh Versus Administration to the Shoulder/Upper Arm
- A Randomized, Double Blind, Placebo and Active Controlled, 3 Way Crossover Study to Evaluate the Electrocardiographic Effects of a Supratherapeutic Dose of Solithromycin in Healthy Men and Women
- Single Dose Study of Hydromorphone and Oxymorphone
- A 7-Days Treatment, One-Center, Randomized, Double-Blind, double-dummy, multiple dose, four-way crossover study to evaluate the effect of XXX on cardiac safety
- An Open-Label, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Electrocardiographic Effects of XXX Following Infusions with Supplementary Injections Compared to Repeated Bolus Injections in Normal Healthy Volunteers
- A Four Period, Four-Arm, Crossover Design, Randomized, Placebo and Active Controlled Study for the Evaluation of the Effect of Therapeutic and Supratherapeutic Single-Dose XXX on the QT/QTc Intervals in Healthy Volunteers.
- A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of XXX for Injection and a Single Supratherapeutic Dose in Healthy Adult Subjects
- A Phase I, Randomized, Double-Blind Within Device, Single-Dose, Four-Period, Six-Treatment, Cross-Over Study Evaluating the Safety and Pharmacokinetics of Three Doses of XXX and XXX, One Dose of XXX and XXX and Two Doses of XXX in Healthy Volunteers.